Pfizer adds $784.6 M charge for Protonix deal to 4Q results

February 16, 2016 by Linda A. Johnson

Drugmaker Pfizer Inc. swung to a fourth-quarter financial loss, instead of a modest profit, as a result of a just-announced charge to settle a long-running federal case over reimbursements for its former blockbuster heartburn pill.

Pfizer, which is planning a mega-acquisition of Irish drugmaker Allergan meant to reduce Pfizer's corporate bill, said Tuesday that it has a tentative agreement to pay the federal government $784.6 million. That would resolve litigation over the calculation of rebates Wyeth paid the government for Medicaid purchases of its severe heartburn treatment, Protonix. The agreement must be approved by U.S. District Judge Douglas P. Woodlock in Massachusetts, Pfizer said.

Pfizer, the largest U.S.-based drugmaker, said it is charging the payment to its fourth-quarter results, which it restated on Tuesday. That left the New York-based company with a loss of $172 million, or 3 cents per share, in the last quarter, compared with a net profit of $613 million, or 10 cents per share, initially reported on Feb. 2.

For all of 2015, Pfizer is now reporting net income of $6.96 billion, or $1.11 per share, down from the $7.75 billion, or $1.24 per share, reported two weeks ago. Pfizer said its adjust results for the quarter will not change.

Protonix heals acid reflux damage to the esophagus. Cheaper generic versions of the drug, known as pantoprazole, came on the market about five years ago and around a dozen are available.

The settlement would resolve cases pending in federal court that centered on Wyeth's practices related to rebates on Protonix sales between 2001 and 2006, when its patent, and market exclusivity, were still in force. Pfizer bought Wyeth in the fall of 2009.

Wyeth is not admitting any liability, which is typical in the many settlements drugmakers reach with federal prosecutors for allegedly overcharging government health programs and other misconduct.

A few years ago, Pfizer paid $55 million to resolve allegations that Wyeth promoted Protonix for uses not approved by the Food and Drug Administration.

Pfizer expects to wrap up its $160 billion purchase of Allergan in the second half of this year, then move Pfizer's official headquarters for tax purposes from New York to Allergan's base in Dublin. The strategy, called a tax inversion, would sharply decrease Pfizer's tax bill from its current U.S. tax rates, though the drugmaker's operational headquarters would remain in New York.

In early-afternoon trading, Pfizer shares rose 32 cents, or 1.1 percent, to $29.68. The broader markets were up by about the same percentage.

Explore further: Pfizer, Allergan CEOs: Tie-up aims for growth, not cost cuts

Related Stories

Pfizer, Allergan CEOs: Tie-up aims for growth, not cost cuts

January 12, 2016
The heads of drugmakers Pfizer and Allergan said Tuesday that the record $160 billion combination they're planning is meant to produce more medicines and boost revenue, not to just slash jobs and other costs as the companies ...

Pfizer settles Protonix patent case for $2.15B

June 12, 2013
Two generic drugmakers will pay $2.15 billion to Pfizer and Takeda Pharmaceutical to settle a patent fight over the heartburn treatment Protonix.

Pfizer to pay $35M to settle drug marketing case

August 6, 2014
Pfizer will pay $35 million to resolve allegations by 42 states that its subsidiary, Wyeth Pharmaceuticals, illegally marketed an organ transplant drug for unapproved uses.

Pfizer, Allergan weigh blockbuster merger: reports

October 29, 2015
Pharmaceutical giant Pfizer recently approached Botox-maker Allergan over what would be the biggest takeover deal this year, The Wall Street Journal said Wednesday.

Pfizer to pay $491M to resolve drug marketing case (Update)

July 30, 2013
The U.S. Justice Department said Tuesday that drugmaker Pfizer Inc. will pay almost $491 million to resolve an investigation into illegal marketing of the organ transplant drug Rapamune by a company Pfizer later acquired.

Shares of Indian units of Pfizer, Wyeth jump on merger approval

November 25, 2013
Shares of the Indian units of US pharmaceutical firms Pfizer and Wyeth soared Monday, after the pair approved a merger plan which would create India's ninth largest drug company.

Recommended for you

Drug overdose epidemic has been growing exponentially for decades

September 20, 2018
Death rates from drug overdoses in the U.S. have been on an exponential growth curve that began at least 15 years before the mid-1990s surge in opioid prescribing, suggesting that overdose death rates may continue along this ...

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

Probiotic use may reduce antibiotic prescriptions, researchers say

September 14, 2018
Use of probiotics is linked to reduced need for antibiotic treatment in infants and children, according to a review of studies that probed the benefits of probiotics, say researchers in the U.S., England and the Netherlands.

Recalled blood pressure drugs not linked to increased short term cancer risk

September 12, 2018
Products containing the withdrawn blood pressure drug valsartan are not associated with a markedly increased short term risk of cancer, finds an expedited analysis published by The BMJ today.

Sugar pills relieve pain for chronic pain patients

September 12, 2018
Someday doctors may prescribe sugar pills for certain chronic pain patients based on their brain anatomy and psychology. And the pills will reduce their pain as effectively as any powerful drug on the market, according to ...

A new approach for finding Alzheimer's treatments

September 11, 2018
Considering what little progress has been made finding drugs to treat Alzheimer's disease, Maikel Rheinstädter decided to come at the problem from a totally different angle—perhaps the solution lay not with the peptide ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.